hims semaglutide ingredients Novo abruptly ends obesity drug deal with GLP-1 Drugs from the Gray

A Phase 1 high-dose trial explored mazdutide at 16 mg and found it well tolerated with even greater weight loss, suggesting the ceiling for mazdutide efficacy has not been reached

Some individuals may experience mild water retention due to increased GH levels

Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline

Generic semaglutide contains the same active ingredient as Ozempic and is therefore expected to have the same side effects